Comparative Pharmacology
Head-to-head clinical analysis: VIZZ versus WILPO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIZZ versus WILPO.
VIZZ vs WILPO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Wilpo (setmelanotide) is a melanocortin 4 receptor (MC4R) agonist that activates the MC4R pathway to reduce appetite and increase energy expenditure.
80 mg orally once daily
WILPO is not a known or approved drug. No standard dosing information available.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours. Steady-state is reached within 4-5 days; accumulation may occur in renal impairment.
Terminal elimination half-life of 12 hours (range 10-14 h). Steady-state achieved after 2-3 days. Requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 60% of a dose is excreted in urine as metabolites, 30% in feces, and <5% unchanged.
Primarily renal (unchanged: 60%, glucuronide conjugate: 20%), biliary/fecal: 15%, other: 5%.
Category C
Category C
Unknown
Unknown